2026.01.09 本文字数：675，阅读时长大约1分钟 作者 |一财阿驴 09:28商业航天板块再度高开，远东股份4连板，中国一重3连板，中衡设计、盛洋科技、巨力索具2连 板。消息面上，广州提出到2035年，打造具有全球影响力的中国商业航天新一极。 09:25 A股开盘丨沪指高开0.09% 沪指高开0.09%，深成指低开0.30%，创业板指低开0.69%，科创综指低开0.47%。 | | 6.68 +0.61 +10.05% | | | 中国石化 1 立即 600028 交易 | | | | --- | --- | --- | --- | --- | --- | --- | | | SSE CNY 9:25:02 交易中 查看L2全景 | | | 好似成持受限 通 品 √ ○ + | | | | 港(0386) | 4.750(+1.71%) H/A:-36.02% | | Wind ESG评级A | | | 详情 | | 委托 | -84.26% 委差 | -93598 | रेस | 8.09% 120日 | | 17.86% | | 或五 | | | 5日 | 8.09% 250日 | | 4.54 ...

2026.01. 09 本文字数：675，阅读时长大约1分钟 | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | NM | 4086.76 | 3.78 | 0.09% | | 399001 | 深证成指 | Myr | 13917.78 | -41.70 | -0.30% | | 399006 | 创业板指 | 14 | 3279.38 | -22.93 | -0.69% | | 000680 | 科创综指 | 1 m | 1758.30 | -8.27 | -0.47% | 盘面上，算力硬件产业链调整，CPO、存储器方向领跌；半导体、锂矿、脑机接口题材跌幅靠前。 房地产、油气板块涨幅靠前，商业航天题材仍局部活跃。 个股方面，中国石化竞价涨停，消息面上，中国石化和中国航油获批实施重组。 | | 6.68 +0.61 +10.05% | | | | 中国石化 1 立即 600028 交易 | | | --- | --- | --- | --- | --- | --- | --- | ...

Group 1 - Hong Kong stocks of certain technology companies opened higher, with Alibaba-W and JD Group-SW rising over 3% [1] - Bilibili-W and Alibaba Health opened 2% higher, while Kingsoft saw an increase of over 1% [1]

Market Overview - The A-share market opened with the Shanghai Composite Index up by 0.09% at 4086.76 points, while the Shenzhen Component Index and the ChiNext Index opened down by 0.30% and 0.69% respectively [2][3] - The Hang Seng Index opened up by 0.47%, with the Hang Seng Tech Index rising by 0.38% [5][6] Sector Performance - Real estate and oil & gas sectors showed strong performance, while the commercial aerospace sector remained active [1] - The computing hardware supply chain experienced adjustments, with CPO and memory sectors leading the declines; semiconductor, lithium mining, and brain-computer interface sectors also saw significant drops [3] Notable Stocks - China Petroleum & Chemical Corporation (Sinopec) hit the daily limit up, following news of its merger approval with China National Aviation Fuel [3] - In the Hong Kong market, new listings such as MiniMax opened significantly higher, with a 42.67% increase, and the company reported a total fundraising amount of approximately HKD 4.818 billion [6][7] Economic Indicators - The People's Bank of China conducted a 7-day reverse repurchase operation of CNY 34 billion at an interest rate of 1.40% [7] - The RMB to USD central parity rate was reported at 7.0128, an increase of 69 basis points from the previous day's rate [8]

Group 1 - JPMorgan Chase & Co. increased its stake in Alibaba Health (00241.HK) by acquiring 46,668,272 shares at an average price of HKD 5.2772 per share, totaling approximately HKD 246 million [1] - Following this acquisition, JPMorgan's total holdings in Alibaba Health rose to 1,314,154,376 shares, increasing its ownership percentage from 7.83% to 8.12% [1][2]

智通财经APP获悉，香港联交所最新资料显示，1月5日，摩根大通增持阿里健康(00241)4666.8272万 股，每股作价5.2772港元，总金额约为2.46亿港元。增持后最新持股数目约13.14亿股，最新持股比例为 8.12%。 ...

香港联交所最新资料显示，1月5日，摩根大通增持阿里健康(00241)4666.8272万股，每股作价5.2772港 元，总金额约为2.46亿港元。增持后最新持股数目约13.14亿股，最新持股比例为8.12%。 ...

中国经济网北京1月8日讯 据同花顺数据显示，在刚过去的2025年12月份，博时恒生医疗保健 (QDII-ETF) 单月下跌10.17%。截至2025年三季度末规模为74.30亿元。 | 代码 名称 | | 12月复权单位 累计单位 | | | --- | --- | --- | --- | | | 净值增长率8 净值元 | | | | 513060. SH 博时恒生医疗保健(QDII-ETF) | -10.17 | 0.59 | 63.02 2021-03-18 万琼 | 来源：同花顺 2025年三季度前十大重仓股为百济神州、药明生物、信达生物、康方生物、中国生物制药、石药集 团、京东健康、三生制药、药明康德、阿里健康。基金经理万琼2004年起先后在中企动力科技股份有限 公司、华夏基金工作。2011年加入博时基金管理有限公司，历任投资助理、基金经理助理、基金经理。 （责任编辑：刘畅 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@s ...

中国经济网北京1月8日讯 据同花顺数据显示，在刚过去的2025年12月份，博时恒生医疗保健 (QDII-ETF) 单月下跌10.17%。截至2025年三季度末规模为74.30亿元。 来源：同花顺 (责任编辑：康博) 2025年三季度前十大重仓股为百济神州、药明生物、信达生物、康方生物、中国生物制药、石药集 团、京东健康、三生制药、药明康德、阿里健康。基金经理万琼2004年起先后在中企动力科技股份有限 公司、华夏基金工作。2011年加入博时基金管理有限公司，历任投资助理、基金经理助理、基金经理。 | 代码 名称 | 12月复权单位 累计单位 规模亿元 基金成立日 基金经理 | | --- | --- | | | 净值增长率8 净值元 | | 513060.SH 博时恒生医疗保健(QDII-ETF) | -10.17 0.59 63.02 2021-03-18 万琼 | ...

Core Insights - Alibaba Health and Beijing Meirsen Pharmaceutical Technology Development Co., Ltd. have formed a strategic partnership to collaborate in the field of innovative drugs for pediatric specialties, specifically focusing on the treatment of infantile hemangiomas with the drug Beimeijing (Timolol Maleate Gel) [1][2] Group 1: Product and Market Overview - Beimeijing is the world's first approved topical innovative drug for the treatment of proliferative superficial infantile hemangiomas, addressing a condition that affects an estimated 5% to 12% of infants globally, with superficial types accounting for nearly 70% of cases [1] - A meta-analysis by the Chinese Medical Association indicates that 25% to 69% of untreated children may experience long-term issues such as scarring and skin laxity, particularly affecting areas like the head and face, which can impact psychological health and social interactions [1] Group 2: Clinical Data and Efficacy - Phase III clinical trial results show that among 121 infants aged 1 to 6 months, 60.7% achieved clinical cure (Grade IV improvement) after 24 weeks of treatment, with an overall efficacy rate of 89.4%, demonstrating good safety and providing a new effective option for patients [1] Group 3: Strategic Initiatives and Future Plans - Beimeijing will be exclusively launched on Alibaba Health's platform on January 13, with plans to initiate the "Infant Hemangioma Care Program," which will integrate expert consultations, educational live streams, medication guidance communities, and public welfare projects to create a comprehensive care loop from awareness to recovery [2] - The collaboration aims to leverage Alibaba Health's ecosystem capabilities alongside Meirsen's expertise in pediatric specialty research, not only to provide a new drug but also to enhance health management solutions for children in China and promote industry standard upgrades [2] - Alibaba Health emphasizes that this strategic partnership is a key step in deepening its vertical disease management capabilities and implementing a patient-centered value strategy, aiming to maximize value through precise outreach, standardized treatment, and long-term management [2]